April 27, 2023

Abbvie pays dearly for miss by its new stars

April 27, 2023

Astra setback typifies slow progress in Wilson’s

April 04, 2023

In with a Ror1, out with a whimper

March 29, 2023

Johnson & Johnson quits RSV while it’s behind

February 27, 2023

Why Blueprint cannot afford another Gavreto

February 23, 2023

Sickle cell pipeline gets edited down

January 06, 2023

Fate runs out of excuses

The plug is pulled on a deal with J&J, and Fate swings the axe over its staff and NK cell pipeline.

November 02, 2022

Opinions diverge on CD39 blockade

October 31, 2022

Abbvie’s ROR ends with a whimper